[go: up one dir, main page]

BR9909422A - Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico - Google Patents

Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico

Info

Publication number
BR9909422A
BR9909422A BR9909422-3A BR9909422A BR9909422A BR 9909422 A BR9909422 A BR 9909422A BR 9909422 A BR9909422 A BR 9909422A BR 9909422 A BR9909422 A BR 9909422A
Authority
BR
Brazil
Prior art keywords
treatment
cardiac hypertrophy
pharmaceutical composition
hypertrophy
heart
Prior art date
Application number
BR9909422-3A
Other languages
English (en)
Inventor
Hongkui Jin
Hsienwie Lu
Nicholas J Paoni
Renhui Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9909422A publication Critical patent/BR9909422A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MéTODO PARA TRATAMENTO DE HIPERTROFIA CARDìACA, MéTODO PARA PREPARAçãO DE COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE HIPERTROFIA CARDìACA E SEU PRODUTO FARMACêUTICO" A invenção se refere ao tratamento da hipertrofia cardíaca por interferon-gama (IFN-<sym>). A hipertrofia cardíaca pode resultar de uma variedade de condições patológicas distintas, incluindo o infarto do miocárdio, a hipertensão, a cardiomiopatia hipertrófica e a regurgitação valvular. O tratamento se estende a todos os estágios do progresso da hipertrofia cardíaca, com ou sem danos estruturais do músculo do coração, independentemente do distúrbio cardíaco subjacente.
BR9909422-3A 1998-04-02 1999-03-19 Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico BR9909422A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8044898P 1998-04-02 1998-04-02
PCT/US1999/006032 WO1999051260A2 (en) 1998-04-02 1999-03-19 Treatment of cardiac hypertrophy

Publications (1)

Publication Number Publication Date
BR9909422A true BR9909422A (pt) 2001-09-11

Family

ID=22157456

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909422-3A BR9909422A (pt) 1998-04-02 1999-03-19 Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico

Country Status (17)

Country Link
US (2) US6187304B1 (pt)
EP (2) EP1702623B1 (pt)
JP (2) JP5030329B2 (pt)
CN (1) CN1201814C (pt)
AR (1) AR018174A1 (pt)
AT (2) ATE410181T1 (pt)
AU (1) AU757910B2 (pt)
BR (1) BR9909422A (pt)
CA (1) CA2325442C (pt)
DE (2) DE69932235T2 (pt)
DK (2) DK1067958T3 (pt)
ES (2) ES2267258T3 (pt)
IL (1) IL138812A0 (pt)
NZ (1) NZ506854A (pt)
TW (1) TWI243682B (pt)
WO (1) WO1999051260A2 (pt)
ZA (1) ZA200004854B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ506854A (en) * 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy
DE60036945T2 (de) * 1999-07-12 2008-08-21 Genentech, Inc., South San Francisco Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
PL213311B1 (pl) * 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
US20050245509A1 (en) * 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
US7972612B2 (en) * 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP2294183B1 (en) * 2008-06-18 2015-12-16 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
USD647411S1 (en) 2011-01-12 2011-10-25 Rain Bird Corporation Water timer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4929544A (en) 1982-04-23 1990-05-29 Sri International Reagents, methods, and test kit for diagnosing/monitoring cancer in humans
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
ATE121945T1 (de) 1989-12-01 1995-05-15 Childrens Medical Center Verwendung von gamma-interferon zur herstellung eines medikaments für die behandlung von steroid- abhängigem asthma.
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
JP3104257B2 (ja) * 1995-08-30 2000-10-30 東レ株式会社 心疾患治療剤
NZ506854A (en) * 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy

Also Published As

Publication number Publication date
EP1067958B1 (en) 2006-07-05
DE69932235D1 (de) 2006-08-17
CN1300221A (zh) 2001-06-20
ATE410181T1 (de) 2008-10-15
DE69932235T2 (de) 2007-06-14
US6187304B1 (en) 2001-02-13
CA2325442C (en) 2011-10-11
JP2009256375A (ja) 2009-11-05
AU757910B2 (en) 2003-03-13
AR018174A1 (es) 2001-10-31
ZA200004854B (en) 2001-09-26
CN1201814C (zh) 2005-05-18
JP2002510645A (ja) 2002-04-09
TWI243682B (en) 2005-11-21
DE69939723D1 (de) 2008-11-20
DK1702623T3 (da) 2009-01-19
HK1036019A1 (en) 2001-12-21
EP1702623B1 (en) 2008-10-08
EP1067958A2 (en) 2001-01-17
WO1999051260A3 (en) 1999-12-09
IL138812A0 (en) 2001-10-31
US6989364B1 (en) 2006-01-24
DK1067958T3 (da) 2006-11-06
EP1702623A2 (en) 2006-09-20
AU3102499A (en) 1999-10-25
EP1702623A3 (en) 2007-01-10
JP5030329B2 (ja) 2012-09-19
WO1999051260A2 (en) 1999-10-14
NZ506854A (en) 2003-07-25
ES2314786T3 (es) 2009-03-16
ATE332144T1 (de) 2006-07-15
HK1099197A1 (en) 2007-08-10
ES2267258T3 (es) 2007-03-01
CA2325442A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
BR9909422A (pt) Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico
Kruger et al. Calcium metabolism, osteoporsis and essential fatty acids: A review
GEHA et al. Intramural ventricular cardiac fibroma: successful removal in two cases and review of the literature
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
SI2336359T1 (sl) 1L1RL-1 kot marker kardiovaskularne bolezni
AU2003264150A1 (en) Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries
CY1110988T1 (el) Ταχεως αποσαθρουμενο στερεο παρασκευασμα
DE60122928D1 (de) Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat
Hudson The cardiomyopathies: order from chaos
Sharma et al. Fabrication, characterization and in vivo assessment of cardiogel loaded chitosan patch for myocardial regeneration
Wainio et al. Enzymes in protein depletion: III. Enzymes of brain, kidney, skeletal muscle and spleen
Falase Endomyocardial fibrosis in Africa
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
Magliocco et al. Dilated cardiomyopathy in multicore myopathy
Effler Chronic constrictive pericarditis treated with pericardiectomy
Bounous et al. Effects of an elemental diet on the pancreatic proteases in the intestine of the mouse
Guo et al. Exercise-induced late preconditioning is triggered by generation of nitric oxide
d'Cruz et al. Sclero-calcific mitral valve changes in patients with chronic renal failure on haemodialysis
Stuver et al. Mechanical abnormalities in the rat ischemic heart failure model which lie downstream to cAMP production
Shibata et al. Possible generation of potent vasocontracting substance from prostaglandin endoperoxide analogs, human platelets mixture.
Sajeev et al. Myocardial infarction in a young woman with antiphospholipid syndrome
Pugliatti et al. Non compaction cardiomyopathy and Antiphospholipid syndrome: A catastrophic thromboembolic association
BR0007894A (pt) Emprego de moxonidina para tratamento apósinfarto cardìaco
Walther et al. Stentless tricuspid valve replacement
Lombard Veterinary Study for the Confirmation of Pimobendan in Canine Endocardiosis–Results of VetSCOPE

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O, 13 DA LPI 9279/06

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.